RxDoctor Payments Data

Alyssa Sader, MD

Family Medicine · Coos Bay, ORNPI 1891170502

Payments from drug & device makers

$459in general payments, 2019–2025

Across 20 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$158
  • AstraZeneca$65
  • GSK$40
  • Exact Sciences$32
  • AbbVie$32
  • Vertex$30
  • plus $104 from 5 others

What the payments were for

  • Food & beverage$44397%
  • Education$163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 80th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$219,863
Medicare patients
399
Services billed
5,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$116,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$37,625
OzempicSemaglutide40$37,610
XareltoRivaroxaban18$27,379
FarxigaDapagliflozin Propanediol23$25,092
JanuviaSitagliptin Phosphate16$15,871
Repatha SureclickEvolocumab18$14,105
Incruse ElliptaUmeclidinium Bromide29$13,548
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$11,761
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,675
Spiriva HandihalerTiotropium Bromide11$7,567
Fiasp FlextouchInsulin Aspart (Niacinamide)11$6,014
Atorvastatin Calcium425$4,977
Albuterol Sulfate HfaAlbuterol Sulfate120$4,643
Solifenacin Succinate23$4,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$116,46695 claims
GSKTrelegy Ellipta, Incruse Ellipta$40$51,17373 claims
Novo NordiskOzempic$26$37,61040 claims
AstraZenecaFarxiga, Breztri Aerosphere, Pulmicort Flexhaler$65$36,75552 claims
AbbVieCreon, Synthroid$32$5,46647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Coos Bay

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →